PBAC's latest decision on Methotrexate: Recommended with restriction (2018). Considered for Severe active rheumatoid arthritis or severe psoriasis (when oral methotrexate is unsuitable, and psoriasis must not have adequately responded to topical treatment).
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
3
first 2016
Submissions
3
2016 → 2018
Eligible population
Adults with severe active rheumatoid arthritis or severe psoriasis who are unsuitable for oral methotrexate administration.
Therapy area
Rheumatology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
Trexject®
Economic model
Cost-minimisation
ICER note
Cost-minimisation; no ICER calculated. Minor submission with expected cost-neutral impact to Government.
Submission history
Mar 2016: Recommended with restriction · Restricted
Mar 2017: Recommended with restriction · Authority Required
Jul 2018: Recommended with restriction · Authority Required